Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study

作者：Dongdong Xia, Wei Bai, Enxin Wang, Jiaping Li, Xiaoming Chen, Zhexuan Wang, Mingsheng Huang, Ming Huang, Junhui Sun, Yang Weizhu, Zhengyu Lin, Jianbing Wu, Zixiang Li, Shufa Yang, Xu Zhu, Zaizhong Chen, Yanfang Zhang, Wenzhe Fan, Qicong Mai, Rong Ding, Chun‐Hui Nie, Long Feng, Xueda Li, Wukui Huang, Jun Sun, Qiuhe Wang, Yong Lv, Xiaomei Li, Bohan Luo, Zhenyu Wang, Jie Yuan, Wengang Guo, Kai Li, B. Li, Ruijun Li, Zhanxin Yin, Jielai Xia, Guohong Han, on behalf of China HCC-TACE Study Group · 发表于：Liver Cancer · 年份：2022 · DOI：10.1159/000523849 · 被引用次数：43 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Cholangiocarcinoma and Gallbladder Cancer Studies、Liver Disease Diagnosis and Treatment

Introduction: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC). We aimed to compare the clinical outcomes of lenvatinib plus drug-eluting beads transarterial chemoembolization (DEB-TACE) versus lenvatinib alone in real-world practice. Methods: This retrospective analysis included 142 consecutive patients who received lenvatinib plus DEB-TACE and 69 patients who received lenvatinib alone as first-line treatment from 15 Chinese academic centers from November 2018 to November 2019. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) were evaluated by modified Response Evaluation Criteria in Solid Tumors criteria, and safety profiles were compared between the two groups. Results: The median OS and PFS were significantly longer in the combined therapy group than in the monotherapy group in whole cohort (median OS, 15.9 vs. 8.6 months, p = 0.0022; median PFS, 8.6 vs. 4.4 months, p &#x3c; 0.001) and after propensity score matching analysis (median OS, 13.8 vs. 7.8 months, p = 0.03; median PFS, 7.8 vs. 4.5 months, p = 0.009). Moreover, the treatment option was an independent prognostic factor for OS and PFS with adjustment based upon baseline characteristics (adjusted hazard ratio [HR]: 0.53, 95% confidence interval [CI]: 0.36...